Chinese General Practice ›› 2022, Vol. 25 ›› Issue (12): 1429-1434.DOI: 10.12114/j.issn.1007-9572.2021.02.131
Special Issue: 肿瘤最新文章合集; 消化系统疾病最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2021-09-23
Revised:
2021-11-12
Published:
2022-01-13
Online:
2022-03-21
Contact:
Tao LI
About author:
通讯作者:
李涛
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.131
临床指标 | 匹配前 | 匹配后 | ||||||
---|---|---|---|---|---|---|---|---|
A组(n=145) | B组(n=201) | t(χ2)值 | P值 | A组(n=92) | B组(n=92) | t(χ2)值 | P值 | |
年龄(岁) | 54.8±7.2 | 56.3±8.6 | 1.875 | 0.213 | 55.3±6.9 | 55.9±6.7 | 0.841 | 0.414 |
性别(男/女) | 102/43 | 145/56 | 2.623a | 0.168 | 61/31 | 59/33 | 0.843a | 0.389 |
肝硬化(是/否) | 90/55 | 121/80 | 2.871a | 0.134 | 50/42 | 47/45 | 1.014a | 0.297 |
病因(乙型肝炎/丙型肝炎/其他) | 80/35/30 | 131/20/50 | 3.542a | 0.061 | 50/22/20 | 49/17/26 | 1.287a | 0.276 |
AFP(μg/L) | 254.1±125.7 | 369.8±143.2 | 12.311 | <0.001 | 289.8±103.5 | 314.7±98.3 | 0.912 | 0.302 |
肿瘤直径(cm) | 3.6±0.7 | 4.5±0.4 | 7.899 | 0.004 | 3.9±0.6 | 4.2±0.3 | 0.868 | 0.379 |
肿瘤包膜(有/无) | 85/60 | 91/110 | 7.235a | 0.009 | 38/54 | 40/52 | 0.823a | 0.458 |
边缘情况(不光滑/光滑) | 55/90 | 123/78 | 6.543a | 0.014 | 45/47 | 47/45 | 0.789a | 0.516 |
AST(U/L) | 45.6±27.5 | 51.2±19.7 | 3.125 | 0.082 | 47.3±21.3 | 48.7±17.6 | 0.647 | 0.874 |
ALT(U/L) | 44.4±22.1 | 48.9±23.6 | 3.019 | 0.104 | 46.7±18.3 | 47.1±13.8 | 0.689 | 0.789 |
总胆红素(μmol/L) | 41.2±11.5 | 38.8±10.3 | 1.654 | 0.257 | 40.6±9.4 | 39.5±8.5 | 0.682 | 0.803 |
NLR | 3.1±1.5 | 4.3±1.3 | 7.899 | 0.005 | 3.7±1.2 | 3.9±1.1 | 0.723 | 0.673 |
Child-Pugh分级(A级/B级) | 81/64 | 118/83 | 1.275a | 0.289 | 48/43 | 46/45 | 0.756a | 0.589 |
Table 1 Comparison of clinical indexes between groups A and B before and after being matched for further comparison by 1:1 nearest neighbor matching
临床指标 | 匹配前 | 匹配后 | ||||||
---|---|---|---|---|---|---|---|---|
A组(n=145) | B组(n=201) | t(χ2)值 | P值 | A组(n=92) | B组(n=92) | t(χ2)值 | P值 | |
年龄(岁) | 54.8±7.2 | 56.3±8.6 | 1.875 | 0.213 | 55.3±6.9 | 55.9±6.7 | 0.841 | 0.414 |
性别(男/女) | 102/43 | 145/56 | 2.623a | 0.168 | 61/31 | 59/33 | 0.843a | 0.389 |
肝硬化(是/否) | 90/55 | 121/80 | 2.871a | 0.134 | 50/42 | 47/45 | 1.014a | 0.297 |
病因(乙型肝炎/丙型肝炎/其他) | 80/35/30 | 131/20/50 | 3.542a | 0.061 | 50/22/20 | 49/17/26 | 1.287a | 0.276 |
AFP(μg/L) | 254.1±125.7 | 369.8±143.2 | 12.311 | <0.001 | 289.8±103.5 | 314.7±98.3 | 0.912 | 0.302 |
肿瘤直径(cm) | 3.6±0.7 | 4.5±0.4 | 7.899 | 0.004 | 3.9±0.6 | 4.2±0.3 | 0.868 | 0.379 |
肿瘤包膜(有/无) | 85/60 | 91/110 | 7.235a | 0.009 | 38/54 | 40/52 | 0.823a | 0.458 |
边缘情况(不光滑/光滑) | 55/90 | 123/78 | 6.543a | 0.014 | 45/47 | 47/45 | 0.789a | 0.516 |
AST(U/L) | 45.6±27.5 | 51.2±19.7 | 3.125 | 0.082 | 47.3±21.3 | 48.7±17.6 | 0.647 | 0.874 |
ALT(U/L) | 44.4±22.1 | 48.9±23.6 | 3.019 | 0.104 | 46.7±18.3 | 47.1±13.8 | 0.689 | 0.789 |
总胆红素(μmol/L) | 41.2±11.5 | 38.8±10.3 | 1.654 | 0.257 | 40.6±9.4 | 39.5±8.5 | 0.682 | 0.803 |
NLR | 3.1±1.5 | 4.3±1.3 | 7.899 | 0.005 | 3.7±1.2 | 3.9±1.1 | 0.723 | 0.673 |
Child-Pugh分级(A级/B级) | 81/64 | 118/83 | 1.275a | 0.289 | 48/43 | 46/45 | 0.756a | 0.589 |
变量 | 赋值 |
---|---|
年龄 | 实测值 |
性别 | 男=1,女=0 |
肝硬化 | 是=1,否=0 |
病因 | 乙型肝炎=2,丙型肝炎=1,其他=0 |
AFP | 实测值 |
肿瘤直径 | 实测值 |
肿瘤包膜 | 无=1,有=0 |
边缘情况 | 不光滑=1,光滑=0 |
AST | 实测值 |
ALT | 实测值 |
总胆红素 | 实测值 |
NLR | 实测值 |
Child-Pugh分级 | B级=1,A级=0 |
CAR | 实测值 |
微血管侵犯 | 是=1,否=0 |
Table 2 Assignment for variables possibly associated with the relationship between C-reactive protein to albumin ratio and microvascular invasion in single small hepatocellular carcinoma included in Logistic regression models
变量 | 赋值 |
---|---|
年龄 | 实测值 |
性别 | 男=1,女=0 |
肝硬化 | 是=1,否=0 |
病因 | 乙型肝炎=2,丙型肝炎=1,其他=0 |
AFP | 实测值 |
肿瘤直径 | 实测值 |
肿瘤包膜 | 无=1,有=0 |
边缘情况 | 不光滑=1,光滑=0 |
AST | 实测值 |
ALT | 实测值 |
总胆红素 | 实测值 |
NLR | 实测值 |
Child-Pugh分级 | B级=1,A级=0 |
CAR | 实测值 |
微血管侵犯 | 是=1,否=0 |
模型 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
单因素Logistic分析 | 1.435 | 0.223 | 10.167 | <0.001 | 4.356 | (3.456,5.019) |
模型2 | 1.012 | 0.176 | 6.234 | 0.009 | 3.019 | (2.315,3.923) |
模型3 | 0.824 | 0.154 | 5.324 | 0.019 | 2.435 | (1.894,2.987) |
Table 3 Logistic regression analyses of C-reactive protein to albumin ratio predicting microvascular invasion in single small hepatocellular carcinoma patients before being matched for further comparison by 1:1 nearest neighbor matching
模型 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
单因素Logistic分析 | 1.435 | 0.223 | 10.167 | <0.001 | 4.356 | (3.456,5.019) |
模型2 | 1.012 | 0.176 | 6.234 | 0.009 | 3.019 | (2.315,3.923) |
模型3 | 0.824 | 0.154 | 5.324 | 0.019 | 2.435 | (1.894,2.987) |
模型 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
单因素Logistic分析 | 1.245 | 0.217 | 10.785 | <0.001 | 4.017 | (3.015,4.986) |
模型2 | 0.916 | 0.164 | 6.785 | 0.012 | 2.567 | (1.896,3.113) |
模型3 | 0.724 | 0.118 | 4.789 | 0.026 | 2.164 | (1.234,2.765) |
Table 4 Logistic regression analyses of C-reactive protein to albumin ratio predicting microvascular invasion in single small hepatocellular carcinoma patients after being matched for further comparison by 1:1 nearest neighbor matching
模型 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
单因素Logistic分析 | 1.245 | 0.217 | 10.785 | <0.001 | 4.017 | (3.015,4.986) |
模型2 | 0.916 | 0.164 | 6.785 | 0.012 | 2.567 | (1.896,3.113) |
模型3 | 0.724 | 0.118 | 4.789 | 0.026 | 2.164 | (1.234,2.765) |
[1] |
|
[2] |
|
[3] |
何泳铸,何坤,黄锐钦,等. 术前预测肝癌微血管侵犯临床评分系统的构建[J]. 中华普通外科杂志,2021,36(2):114-117. DOI:10.3760/cma.j.cn113855-20200416-00302.
|
[4] |
|
[5] |
|
[6] |
中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志,2017,33(8):1419-1431. DOI:10.3969/j.issn.1001-5256.2017.08.003.
|
[7] |
|
[8] |
丛文铭,吴孟超. 努力提高我国肝癌微血管侵犯的精细化诊断和个体化治疗水平[J]. 中华肝胆外科杂志,2019,25(10):721-724. DOI:10.3760/cma.j.issn.1007-8118.2019.10.001.
|
[9] |
|
[10] |
张小晶,刘静,刘坤,等. 微血管侵犯对肝癌肝切除术后预后的影响[J]. 中华消化外科杂志,2018,17(5):483-487. DOI:10.3760/cma.j.issn.1673-9752.2018.05.012.
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[1] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
[2] | ZHOU Wenjing, SHANG Shili, YANG Qian, FENG Yuerong, LI Jun. Correlation of Platelet-albumin Ratio with Clinicopathological Features of IgA Nephropathy [J]. Chinese General Practice, 2023, 26(29): 3657-3664. |
[3] | CHEN Weixiang, YIN Renlin, LING Lin, ZHANG Chi, JIANG Tingbo, LIN Jia. Correlation between C-reactive Protein to Albumin and Coronary Collateral Circulation in Patients with Unstable Angina Pectoris [J]. Chinese General Practice, 2023, 26(27): 3430-3434. |
[4] | LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268. |
[5] | SUN Zhenzhen, LIU Huanhuan, CHEN Kaining, LOU Qingqing. New Advances in the Value of the Normal Urinary Albumin as a Predictor of Multiple Diseases [J]. Chinese General Practice, 2022, 25(33): 4191-4195. |
[6] | WU Fanying, LYU Wu, DU Kun, ZHOU Jingfan, HUANG Guolin, FENG Jie. Cancer Incidence Trend in Chinese Longevity Town Cenxi City from 2016 to 2020 [J]. Chinese General Practice, 2022, 25(32): 4079-4084. |
[7] | Jinfa XU, Wencan SONG, Zhongxian ZHENG, Yu BAO, Gaoyan HUA, Qing CAI, Weiwei SHI, Xiufang ZHANG, Jianhua ZHANG, Zhou TONG, Guoan XIA, Fei LIU, Lintao LIU, Kesheng XIAO. Efficacy of China-produced Camrelizumab with Apatinib for First-line Treatment in Middle and Advanced Stages of Primary Liver Cancer [J]. Chinese General Practice, 2022, 25(26): 3258-3262. |
[8] | Huahua HUANG, Tao TIAN, Dongmei ZHANG, Hong LIU, Xubo LI, Wenyuan MA. A Comparative Study of Four Nutritional Evaluation Methods in Prognostic Evaluation of Elderly Patients with Chronic Heart Failure [J]. Chinese General Practice, 2022, 25(24): 3029-3035. |
[9] | Zimo PAN, Lin CHU, Lingxia CHEN, Jingtong WANG. Association of Metrics Derived from a Flash Glucose Monitoring System with Urine Albumin-to-creatinine Ratio in T2DM Patients [J]. Chinese General Practice, 2022, 25(23): 2856-2863. |
[10] | Yilin MA, Jiangfeng KE, Junwei WANG, Lianxi LI. Relationship between Obesity and Proteinuria in Type 2 Diabetic Patients [J]. Chinese General Practice, 2022, 25(20): 2457-2461. |
[11] | Tuoheti YAKUFU·, Kainan ZHANG, Hui ZHAO, Dawuti WUBULITALIFU·, Rui ZHANG, Renyong LIN, Guodong LYU. Performance of Serum m3AchR-Ab for Alpha-fetoprotein-negative Hepatocellular Carcinoma Diagnosis [J]. Chinese General Practice, 2022, 25(17): 2110-2114. |
[12] | Shili SHANG, Zijuan SUN, Lina BI, Wenjing ZHOU, Daiyu SHEN, Jingshan CHEN, Sha LUO, Yuerong FENG, Qian YANG, Jun LI. Influencing Factors of Anemia in Patients with Diabetic Kidney Disease [J]. Chinese General Practice, 2022, 25(12): 1464-1469. |
[13] | LU Zuowei,LIU Tao,LIU Xiangyang,WANG Qiong,LAI Jingbo,CHEN Yanyan,LI Xiaomiao. Construction and Verification of a Predictive Model for Microalbuminuriain Type 2 Diabetes Mellitus Patients [J]. Chinese General Practice, 2021, 24(36): 4653-4660. |
[14] | ZHU Zhuanzhuan,ZHAO Li,LI Yanyan,XIA Hong,DAI Meiqing,GUO Chang,YU Fan,YUAN Guoyue,YANG Ling,WANG Dong. Relationship between Triglyceride-glucose Index and Albuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2021, 24(3): 292-297. |
[15] | LU Changan,WANG Jian,LUO Jinbing,XIA Lijun,HAO Shiwei,ZHAO Ruiquan,WANG Meng,SONG Fei,ZHANG Mingbao,YANG Guangran. Changes in Glomerular Filtration Rate and Urinary Albumin in Type 2 Diabetes in a Community [J]. Chinese General Practice, 2021, 24(18): 2275-2280. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||